| VG161 / ViroGin Biotech |
NCT06126510: Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 40 | RoW | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell), VG161 | CNBG-Virogin Biotech (Shanghai) Ltd. | Sarcoma | 07/25 | 01/26 | | |
NCT05223816: An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 97 | US | VG161, Nivolumab Injection [Opdivo] | Virogin Biotech Canada Ltd | Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma | 10/25 | 12/25 | | |
NCT05162118: Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer |
|
|
| Recruiting | 1/2 | 51 | RoW | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab, VG161 + Nivolumab | Zhejiang University | Advanced Pancreatic Cancer | 03/25 | 12/25 | | |
NCT06008925: Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer |
|
|
| Recruiting | 1/2 | 43 | RoW | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), VG161, Nivolumab Injection, OPDIVO | CNBG-Virogin Biotech (Shanghai) Ltd. | Metastatic Gastric Cancer | 12/25 | 06/26 | | |
NCT06124001: Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 1/2 | 36 | NA | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), VG161, camrelizumab for Injection, camrelizumab | CNBG-Virogin Biotech (Shanghai) Ltd. | Primary Hepatocellular Carcinoma | 12/25 | 06/26 | | |
